Shares of Werewolf Therapeutics Inc. (NASDAQ:HOWL) reflected enthusiasm on Wall Street for the prospect, albeit early stage, of systemically delivering a masked native interleukin-2 (IL-2) cytokine to cancer patients.
HC Wainwright reissued their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL – Free Report) in a report issued on Tuesday morning, Benzinga reports. The brokerage currently has a $15.00 target price on the stock. Separately, Wedbush began coverage on shares of Werewolf Therapeutics in a report on Wednesday, August 23rd. They issued an outperform […]
Werewolf Therapeutics, Inc. announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company?s lead clinical program, WTX-124x2101. This clinical.